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IMPORTANCE Laser-assisted drug delivery (LADD) is used for various medical and cosmetic
applications. However, there is insufficient evidence-based guidance to assist clinicians
performing LADD.
OBJECTIVE To develop recommendations for the safe and effective use of LADD.
EVIDENCE REVIEW A systematic literature review of Cochrane Central Register of Controlled
Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications
reporting research on LADD. A multidisciplinary panel was convened to draft
recommendations informed by the systematic review; they were refined through 2 rounds of
Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous
consensus was achieved.
FINDINGS Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4
were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6
publications of nonablative fractional LADD were included at the request of the expert panel,
producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of
bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that
informed the guidelines developed by the expert panel were as follows: LADD is safe in adults
and adolescents (ⱖ12 years) with all Fitzpatrick skin types and in patients with
immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous
cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for
epidermal and dermal analgesia; drug delivery may be increased through the application of
heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be
selected to ensure that channel diameter is greater than the delivered molecule; antibiotic
prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis
is recommended when treating the face and genitalia; and antifungal prophylaxis is not
recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I)
indications and contraindications; (II) parameters to report; (III) optimization of drug delivery;
(IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.
CONCLUSIONS AND RELEVANCE This systematic review and Delphi consensus approach
culminated in an evidence-based clinical practice guideline for safe and effective use of LADD
in a variety of applications. Future research will further improve our understanding of this
novel treatment technique.
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T

he protective barrier provided by the stratum corneum
limits transcutaneous drug bioavailability, which may be as
low as 1% to 5%.1 Recently, there has been interest in using
laser- and energy-based devices to improve transcutaneous absorption. In particular, laser-assisted drug delivery (LADD) may increase drug efficacy without increasing systemic adverse events.
Since LADD was first reported in 1987,2 the technique has rapidly
evolved. One development was the introduction of fractional photothermolysis, which creates microscopic, vertical channels of ablation surrounded by layers of coagulated tissue.2-4 Both ablative fractional (AF) and nonablative fractional (NAF) devices have been used
with LADD.5-7 Laser-assisted drug delivery has been associated with
various indications, ranging from epidermal analgesia to treatment
of nonmelanoma skin cancer. Interest in the clinical applications of
LADD among dermatologists has substantially grown during the past
decade as clinicians and patients increasingly seek effective, directed, lower-risk interventions for indications that traditionally required higher doses of topical or systemic medication. Given the rapidly expanding collection of clinical research assessing the efficacy
and safety of LADD, this technology is likely to be adopted as a
common tool across dermatology.
To our knowledge, there are presently no evidence-based
clinical practice guidelines for LADD. The objective of this clinical
practice guideline was to delineate applications of LADD and
offer recommendations for safe and effective use.

In accordance with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, recommendationswerecategorizedinto2types:(1)strongrecommendations(eg,
based on randomized clinical trials with low risk of bias, consistency
in results, and without publication bias), signified by the statement
“we recommend”; and (2) conditional recommendations (eg, based
on lower quality studies or observational studies, and in which variations in care may be more acceptable), signified by the statement
“we suggest.”

Methods

Results

This study was approved by the Northwestern University Institutional Review Board (STU00097285). Informed consent was not required because the study used only previously published and publicly available data. Reporting was in accordance with the Appraisal
of Guidelines for Research & Evaluation II (AGREE II) guidelines.

In total, 48 published studies of AF LADD met inclusion criteria (eFigure in the Supplement): 4 cosmetic studies,13-16, 21 oncologic,17-37
and 23 medical (not cosmetic/oncologic).38-60 In addition, 6 publications of NAF LADD61-66 were included at the request of the
expert panel, for a total of 54 studies.
Studies varied in quality and were generally small, singlecenter, randomized clinical trials. For certain topics related to LADD,
the evidence was of sufficient quality but limited quantity. In these
cases, recommendations were based primarily on consensus of expert opinion and in accordance with the Institute of Medicine standards for developing trustworthy clinical practice guidelines.67 Thirtyfour studies (63.0%) were deemed to have low risk of bias, 17 studies
(31.5%) had moderate risk, and 3 (5.5%) had serious risk (eTable 2
in the Supplement).
Delphi surveys were conducted in July to December 2020. The
first Delphi survey was completed by 30 participants, and the second, by 29 (97% retention). Demographic characteristics of participants are shown in Table 1. Overall, 308 items were presented in the
first round, during which 9 additional items were proposed by the
Delphi participants. In the second round, 317 items or subparts were
presented for rating, and 201 (63.4%) met provisional inclusion criteria. Of these 201 items, 107 were included solely to facilitate discussion, 17 to explore future directions in LADD research, and the
remaining 77 as potential actionable items that could become additional recommendations. After an iterative review by a committee of the whole comprised of all Delphi participants and select research personnel, the 77 actionable items were combined into 15 final
recommendations (similar items were grouped together). The final recommendations were reviewed by patient-members.

Guideline Questions
This clinical practice guideline was developed to address the following clinical questions:
I. What are the indications and contraindications for LADD?
II. What are the most important parameters to report for LADD?
III. How can drug delivery be enhanced with LADD?
IV. What are the important safety considerations for LADD?
V. Is prophylaxis (eg, for bacterial, viral, and fungal infection) required for LADD, and if so, in which circumstances?

Guideline Development Process
A multidisciplinary panel of expert stakeholders representing dermatology,pediatricdermatology,hematologyandoncology,internalmedicine, and plastic surgery was assembled based on publication history
(including prior publication of guidelines related to laser- or energybased devices), clinical expertise, peer nomination, and recognition as
thought leaders in related areas of research.
The results of a systematic review (available in eMethods 1 in
the Supplement) and panel deliberations were used to develop a long
list of items related to LADD.8-10 Then this list was critically evaluated and refined through 2 rounds of Delphi surveys and 2 virtual
consensus meetings, with all panel members as Delphi participants (eTable 1 and eMethods 2 in the Supplement).11,12
E2

Key Points
Question Which best practices are associated with the safe and
effective use of laser-assisted drug delivery (LADD)?
Findings This systematic review of 54 studies of LADD informed a
multidisciplinary panel of experts and patient representatives who
used a Delphi consensus process to develop and refine a guideline
for its safe and effective use. The 15 recommendations address 5
areas: indications and contraindications, parameters to report,
optimization of drug delivery, safety considerations, and
antimicrobial prophylaxis.
Meaning This clinical practice guideline provides a current
framework to clinicians for the safe and effective use of LADD in
various medical and cosmetic settings.
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Table 1. Demographic Characteristics of the 30 Delphi Participants
Characteristic
Medical specialty

Participants, No. (%)

Internal medicine

1 (3.3)

Dermatology

26 (86.7)

Pediatric dermatology

1 (3.3)

Plastic and reconstructive surgery

1 (3.3)

Oncology

1 (3.3)

Country represented
Denmark

1 (3.3)

United Arab Emirates

1 (3.3)

US

28 (93.3)

Sex
Female

9 (30.0)

Male

21 (70.0)

Review Clinical Review & Education

of the expert panel from their own clinical experience (Table 3), there
was sufficient evidence to strongly recommend that LADD is safe
and effective for the treatment of actinic keratoses,17-37 actinic
cheilitis,33 and cutaneous squamous cell carcinoma in situ.61,62 In general, it was found that LADD is most effective for treating these
indications, with this typically performed with laser followed by
photodynamic therapy (PDT). Additional research is needed to
determine the efficacy and safety of LADD with PDT for deeper or
more nodular lesions. Pretreatment with AFL before PDT is preferred over pretreatment with NAFL. Two AFL modalities were
reported: erbium-doped yttrium aluminium garnet laser (Er:YAG)
and carbon dioxide (CO2) laser. There were no randomized clinical
trials comparing these 2 modalities, and it was the opinion of the
expert panel that either Er:YAG or CO2 lasers may be appropriate.
Regarding PDT, either methylaminolevulinate or aminolevulinic
acid may be utilized.

Disclaimer
These guidelines are provided to assist with clinical decisionmaking but are not a standard of care. Based on patient- and clinicianspecific considerations, treating physicians may select courses of action other than those suggested. The panel and the authors assume
no responsibility and make no warranty regarding the information
provided.

Recommendation 4. We suggest the use of LADD for the treatment
of hypertrophic scars and keloids (level of evidence: low; recommendation: conditional). | With CO2 or Er:YAG lasers, AF LADD is likely

I. Indications and Contraindications

a safe and effective treatment for hypertrophic or keloid scars caused
by burns, traumatic wounds, and vaccinations.46-51,65 Recommended topical agents include 5-fluorouracil and corticosteroids (eg,
ointment, cream, or aqueous solution); verapamil hydrochloride may
also be considered. Multiple treatments, often at 1-month intervals, are often required to attain the desired clinical result.46,49 Patients tend to tolerate these treatments well, although reported adverse events include increased scar telangiectasia, postinflammatory
hyperpigmentation, and transient treatment-related effects such as
pain, burning sensation, and edema.16,70

Recommendation 1. We recommend the use of LADD in adults and
adolescents with all Fitzpatrick skin types (level of evidence: moderate; recommendation: strong). | Laser-assisted drug delivery is con-

Recommendation 5. We recommend the use of LADD for epidermal
and dermal analgesia if there is sufficient time for application (level
of evidence: moderate; recommendation: strong). | In general, a single

sidered to be safe for both adults (ⱖ18 years) and adolescents (12
to <18 years); most studies referenced only transient laser-related
adverse effects (eg, pain, erythema, crusting), and there were few
reports of posttreatment infection.15 Although LADD has also been
used in children, often for analgesia or the treatment of scars, there
is considerably less data for this population compared with
adults.38,47 If LADD is performed in children, it should be done so
with caution because the safety margin is narrower given their reduced body surface area.

treatment with AFL (Er:YAG or CO2) followed by 5 to 15 minutes of
topical anesthetic under occlusion has been associated with significant pain reduction following skin procedures, such as percutaneous procedures, in both pediatric and adult patients. The topical anesthetic agents recommended include 4% tetracaine in benzoyl
alcohol and topical lidocaine without epinephrine. Higher density
settings provide more effective anesthesia compared with lower density, regardless of the laser modality used, and are typically welltolerated by patients. Laser-assisted analgesia may be particularly
useful in patients undergoing multiple procedures, especially children or others less likely to tolerate pain. The laser surgeon should
not exceed the recommended dosing for intralesional injection of
the delivered drug.38-45

Final Recommendations for Use of LADD
These 15 recommendations organized into 5 categories were found
to be associated with the safe and effective use of LADD. Table 2
provides a summarized list along with GRADE ratings.

Recommendation 2. We suggest that LADD may be safely used in
patients with immunosuppression disorders (level of evidence: low;
recommendation: conditional). | There are few published studies of

LADD in patients who are immunosuppressed, but there have been
no reported serious adverse events in this population.19,26,68 The expert panel determined that LADD is likely safe to use in patients who
are immunosuppressed, but that additional research is needed in
this population.
Recommendation 3. We recommend the use of LADD for the treatment of actinic keratoses, actinic cheilitis, and cutaneous squamous
cell carcinoma in situ (level of evidence: moderate; recommendation: strong). | Although there are many indications for LADD as iden-

tified through the systematic review and as reported by members
jamadermatology.com

Recommendation 6. We recommend LADD be deferred in patients
with known allergy to the drug being delivered, active local skin
infection, or who have an underlying medical problem or enzyme
abnormality if the drug is at risk of worsening the abnormality (level
of evidence: moderate; recommendation: strong). | Laser-assisted

drug delivery should not be used in patients with a known allergy
to the drug, in patients with active infection at the treatment site,
or in patients with an underlying medical problem that would be
exacerbated by the drug (eg, dihydropyrimidine dehydrogenase deficiency for 5-fluorouracil). Also, laser surgery is relatively contrain(Reprinted) JAMA Dermatology Published online August 17, 2022
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Table 2. Summary of Recommendations for Laser-Assisted Drug Delivery (LADD)
GRADE rating
Category and recommendation
Indications and contraindications

Evidencea

Strengthb

We recommend the use of LADD in adults (≥18 y) and adolescents (≥12 to <18 y)
with all Fitzpatrick skin types.
We suggest that LADD may be safely used in immunosuppressed patients.

Moderate

Strong

Low

Conditional

Moderate

Strong

We recommend the use of LADD for the treatment of actinic keratoses, actinic
cheilitis, and cutaneous squamous cell carcinoma in situ.
We suggest the use of LADD for the treatment of hypertrophic scars and keloids.

Low

Conditional

We recommend the use of LADD for epidermal and dermal analgesia if there is
sufficient time for application.
We recommend LADD be deferred in patients with known allergy to the drug being
delivered, active local skin infection, or who have an underlying medical problem or
enzyme abnormality if the drug is at risk of worsening this abnormality.
Parameters to report

Moderate

Strong

Moderate

Strong

We recommend that the following parameters be reported when performing AF and
NAF LADD: fluence/channel depth, density/surface area, spot size, incubation time
(time between laser delivery and medicine application), number of passes, and total
volume and type of formulation of medication applied.
Optimization of drug delivery

Moderate

Strong

We suggest that drug delivery via LADD may be increased by using heat, pressure,
occlusion, and/or low viscosity drug formulations.
We suggest that AF laser settings be selected to ensure that the expected channel
diameter is greater than the diameter of the particle being delivered.
We suggest that cold, non-hollow bore microneedling (without heat or
radiofrequency) or radiofrequency microneedling may be alternative modalities to
laser for drug delivery.
Safety considerations

Low

Conditional

Low

Conditional

Low

Conditional

We recommend that physicians using LADD appreciate that there is a certain
unpredictability of response and tissue levels of drug owing to variable
pharmacokinetics.
We recommend that physicians using LADD be cautious that systemic adverse effects
owing to inadvertent systemic delivery of medications are a possibility.
We recommend LADD be performed with appropriate eye protection (appropriate for
the laser platform), surgical masks, and gloves (level of evidence: moderate;
recommendation: strong), and suggest a smoke evacuator be used, particularly with
AF devices (level of evidence: low; recommendation: conditional).
We suggest LADD only be used with medication formulations approved by a national
regulatory authority for parenteral injection.
Prophylaxis for bacterial, viral, and fungal infections

Moderate

Strong

Moderate

Strong

Low

Conditional

Low

Conditional

We suggest the following prophylaxis regimens for AF and NAF LADD in otherwise
healthy adult, pediatric, and patients who are immunosuppressed: (1) antibiotic
prophylaxis is not recommended when treating areas other than where wound healing
might be impaired (eg, genitalia, lower legs); (2) antiviral prophylaxis is
recommended when LADD is used on the face or genitalia; and (3) antifungal
prophylaxis is not recommended.

Low

Conditional

dicated in women who are pregnant or breastfeeding. We suggest
that LADD also be relatively contraindicated in women who are pregnant or breastfeeding. That being said, while specific medications
may not be appropriate in this context, the use of laser to facilitate
delivery into the skin likely does not increase risk.
II. Parameters to Report
Recommendation 7. We recommend that the following parameters be
reported when performing AF and NAF LADD: fluence/channel depth,
density/surface area, spot size, incubation time (time between laser
delivery and medicine application), number of passes, and total volume and type of formulation of medication applied (level of evidence:
moderate; recommendation: strong). | Laser surgeons should adjust

the standard AFL and NAFL parameters (eg, fluence/channel depth,
density/surface area, spot size, incubation time, number of passes,
and total volume and type of formulation of medication applied) accordingly based on the device being used, the condition being
treated, and the depth of the skin lesion.70-76 While higher fluences can create deeper laser channels, depth does not necessarily
E4

Abbreviations: AF, ablative fractional;
GRADE, Grading of
Recommendations Assessment,
Development and Evaluation;
NAF, nonablative fractional.
a

Quality of evidence was assessed in
accordance with GRADE
methodology and rated from 1-4 as
very low, low, moderate, or high.

b

The strength of each
recommendation was assessed in
accordance with GRADE
methodology and rated as 1 (strong)
or 2 (conditional).

improve absorption. In addition, higher fluences deliver more heat
to the skin, increasing the risk of local adverse events such as pain,
burns, and scarring. There may also be an increased likelihood of
these adverse events with increased density and number of passes.
When performing LADD, the laser surgeon should consider that densities greater than 5% may not offer further improvement in cutaneous drug concentrations or treatment efficacy, and that the risks
of treatment-related adverse events are higher.70 Finally, applying
the drug soon after laser treatment increases drug absorption and
efficacy. Systematic reporting of LADD parameters may facilitate replication of successful treatments as well as more precise adjustment of treatment parameters if required.
III. Optimization of Drug Delivery
Recommendation 8. We suggest that drug delivery via LADD may
be increased by using heat, pressure, occlusion, and/or low viscosity
drug formulations (level of evidence: low; recommendation:
conditional). | To increase drug absorption and efficacy, the treat-

ing physician may use techniques such as heat, pressure, or occlu-
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Table 3. Laser-Assisted Drug Delivery (LADD) Indications Discussed by Guideline Panel Members
GRADE rating

Actinic cheilitis

Examples of topical agents administered
with LADDa
Methylaminolevulinate; aminolevulinic acid;
calcipotriol
Fluorouracil; methylaminolevulinate;
aminolevulinic acid
Methylaminolevulinate; aminolevulinic acid

Moderate

Strong

Analgesia

Lidocaine

Moderate

Strong

Hypertrophic scars

Low

Conditional

Low

Conditional

Basal cell carcinoma

Verapamil hydrochloride; 5-fluorouracil;
corticosteroids
Verapamil hydrochloride; 5-fluorouracil;
corticosteroids
Fluorouracil; methyl aminolevulinate

Hypopigmented scars

Bimatoprost; latanoprost

Indications
Actinic keratoses
Squamous cell carcinoma in situ

Keloidal scars

Onychomycosis

Tazarotene; tioconazole; amorolfine lacquer

Melasma

Hydroquinone; tranexamic acid

Acne vulgaris

Methyl aminolevulinate

Macular amyloid

Vitamin C; corticosteroids

Vitiligo

Betamethasone

Condyloma

5-aminolevulinic acid

Palmar hyperhidrosis

Onabotulinum toxin A

Psoriasis

Calcipotriol

Skin rejuvenation

Aminolevulinic acid

Rhytids

Poly-L-lactic acid

Androgenetic alopecia

Minoxidil; minoxidilalone

Morphea or scleroderma

Poly-L-lactic acid

Sclerodermoid graft-vs-host disease

Clobetasol

Local inflammatory arthritis

Diclofenac

Angiofibroma

Rapamycin

sion after medication application.77-82 Regarding the drug vehicle,
low viscosity formulations, such as aqueous solutions, lotions, or gels,
appear to be more effective at filling laser channels, accelerating
medication delivery. However, because of the prolonged contact
time, occlusion, and hydration afforded by these vehicles, high viscosity formulations, such as creams or ointments, may be preferred.7
Ultimately, the techniques used to increase drug absorption should
be selected based on the underlying disease being treated, treatment location, and patient considerations.
Recommendation 9. We suggest that AF laser settings be selected
to ensure that the expected channel diameter is greater than the
diameter of the particle being delivered (level of evidence: low; recommendation: conditional). | Ensuring that the expected channel di-

ameter is greater than the diameter of the particle being delivered
may improve drug penetration. Although the molecular weight of a
drug is unlikely to limit its ability to penetrate through a channel
created by laser, penetrance may be limited by the effective particle size, particularly if the drug is delivered by a polymer, microsphere, liposome, nanoparticle, or similar means. No specific recommendations were made regarding channel depth, which depends
on fluence, and describes how deeply ablated laser channels extend into the skin. Theoretically, the greater the depth, the more extensively the drug being delivered may penetrate, although in practice greater penetration depth does not necessarily improve
absorption. However, hydrophilic, and hydrophobic substances react differently to channel depth. For hydrophilic medications, deeper
channels may allow for increased drug penetration. Ultimately, chanjamadermatology.com

Evidenceb
Moderate

Strengthb
Strong

Moderate

Strong

Panel did not offer
recommendation

Abbreviation: GRADE, Grading of
Recommendations Assessment,
Development and Evaluation.
a

These are provided for illustrative
purposes and are based on
published reports.14-66,68,69

b

Level of evidence and strength of
recommendation were determined
by the guideline panel for the
specific indication, but not
necessarily for a particular
technique or topical agent.

nel diameter and depth should complement the drug in question as
well as the disease being treated.69,82
Recommendation 10. We suggest that cold, nonhollow bore microneedling (without heat/radiofrequency) or radiofrequency microneedling may be alternative modalities to laser for drug delivery
(level of evidence: low; recommendation: conditional). | Nonlaser mo-

dalities, such as cold nonhollow bore microneedling or insulated or
non-insulated radiofrequency microneedling, may also be used for
drug delivery.83 These approaches may be helpful for patients who
decline laser, or in whom laser is contraindicated. Further research
may clarify the safety and efficacy of these treatment modalities and
how they enable drug penetration. Microneedles can be of various
bores and lengths, with or without insulation or radiofrequency energy, and hence, may behave differently. Although a recent study
using optical coherence tomography found that microneedling and
radiofrequency microneedling did not create observable cutaneous channels,84 other recent research suggests that in some cases
microneedling may facilitate increased penetration and greater lateral extension of the drug as compared with AF laser.83
IV. Safety Considerations
Recommendation 11. We recommend that physicians using LADD
appreciate that there is a certain unpredictability of response and
tissue levels of drug owing to variable pharmacokinetics (level of
evidence: moderate; recommendation: strong). | Overall, LADD is a

safe and effective procedure. Adverse events, when they occur, are
(Reprinted) JAMA Dermatology Published online August 17, 2022
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most often transient and mild (eg, crusting, erythema, postinflammatory hyperpigmentation, and burning sensation). However, we
caution laser surgeons that there is a degree of unpredictability of
response and drug tissue levels owing to variable pharmacokinetics when drugs are delivered through the skin with laser or other energy-based devices.70 Additionally, there may be a slightly increased risk of drug-related local adverse events compared with
administration of the same medication without energy-based
devices.
Recommendation 12. We recommend that physicians using LADD
be cautious because systemic adverse effects owing to inadvertent
systemic delivery of medications are a possibility (level of evidence:
moderate; recommendation: strong). | Theoretically, as with any

parenteral medication, systemic adverse events are a possibility in
LADD. To minimize risk, small volumes should be used (commonly
1-2 mL). A detailed past medical history, including an updated medication list and allergies, should be obtained before treatment.
Recommendation 13. We recommend LADD be performed with appropriate eye protection (appropriate for the laser platform), surgical masks, and gloves (level of evidence: moderate; recommendation: strong), and suggest using a smoke evacuator, particularly with
AF devices (level of evidence: low; recommendation: conditional). |

When performing LADD, we recommend that the laser surgeon
wear appropriate, device-specific protective equipment, ie, eye protection specific to the laser, a surgical mask, and surgical gloves. For
AFL, we suggest that the surgeon consider the use of a smoke
evacuator. Additionally, when treating viral lesions, the surgeon may
consider wearing an N95 mask to address the risk of acquired laryngeal papillomatosis.
Recommendation 14. We suggest LADD only be used with medication formulations approved by a national regulatory authority for
parenteral injection (level of evidence: low; recommendation:
conditional). | Only medications approved by the appropriate regu-

latory authority (eg, US Food and Drug Administration) for injection into the skin, subcutaneous tissue, or intravascular space should
be used for LADD. Although necessary, such approval may be insufficient to ensure safety (eg, phenytoin approved for IV use may cause
tissue necrosis when it penetrates deep into the skin). Medications
indicated only for topical use, such as many cosmeceuticals, moisturizers, topical corticosteroids, topical antibiotics, and antiseptics, and many other over-the-counter and prescription medicaARTICLE INFORMATION
Accepted for Publication: June 17, 2022.
Published Online: August 17, 2022.
doi:10.1001/jamadermatol.2022.3234
Author Affiliations: Department of Dermatology,
Feinberg School of Medicine, Northwestern
University, Chicago, Illinois (Labadie, Ibrahim,
Worley, Kang, Christensen, Poon, Alam); Chicago
Medical School, Rosalind Franklin University of
Medicine and Science, North Chicago, Illinois
(Rakita, Rigali); SkinCare Physicians, Chestnut Hill,
Massachusetts (Arndt, Dover); Department of
Dermatology, Warren Alpert Medical School of
Brown University, Providence, Rhode Island (Arndt,
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tions should not be delivered with laser as they may induce sensitivity
reactions, granulomas, infections, and systemic adverse reactions.
V. Prophylaxis for Bacterial, Viral, and Fungal Infections
Recommendation 15. We suggest use of the following prophylaxis
regimens for AF and NAF LADD in otherwise healthy adults, pediatric patients, and patients who are immunosuppressed: antibiotic
prophylaxis is not recommended when treating areas other than
where wound healing might be impaired (eg, genitalia, lower legs);
antiviral prophylaxis is recommended when LADD is used on the
face or genitalia; and antifungal prophylaxis is not recommended
(level of evidence: low; recommendation: conditional). | Antibacte-

rial prophylaxis should be reserved for sites with a high possibility
of poor wound healing, such as genitalia or lower legs. Antiviral prophylaxis should be offered when treating the face or genitalia, regardless of herpes simplex virus history. Based on limited evidence, antifungal prophylaxis is typically not needed. Data were
insufficient to recommend alterations of prophylaxis regimen based
on patient age or immunosuppression status.

Limitations
Laser-assisted drug delivery is a novel technology that is rapidly
evolving. There may yet be substantial changes over time in how
LADD is routinely performed and, consequently, in its safety and effectiveness. Therefore, the current guidelines may need to be revised in the future. Although LADD is a relatively new technology,
the current guidelines are important to ensure that practitioners and
patients have an understanding of how it should be performed and
what are its benefits and limitations. These guidelines may also
assist in identifying areas of uncertainty to address with future
research.

Conclusions
The findings of this systematic review and Delphi consensus study
suggest that LADD can be a safe and effective treatment for various indications. As the standard of care continues to shift toward
minimally invasive and individualized methods of drug delivery, LADD
will play an important role. Future research will bolster understanding of these promising procedures and how they may be further optimized for clinical effectiveness while maintaining a high level of
therapeutic safety.
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